**RKTO is the new ticker symbol (effective May 28, 2026) for Rocket One Inc., formerly Hoth Therapeutics (HOTH).**
It is a **small-cap/nanocap company** (market cap in the low tens of millions) that has pivoted from clinical-stage biotech to developing infrastructure for the "orbital economy" — specifically **next-generation nanomagnetic AI chip technology** for ultra-low-power, radiation-tolerant computing in space (satellites, low-Earth orbit, deep space) and defense applications.
# What’s Moving It
* **Primary catalyst**: The rebrand/name change + ticker update to RKTO, combined with the strategic pivot to **space + AI narrative**. This is a classic momentum play in hot sectors (space economy / AI hardware). The stock surged dramatically (around 90%+ on May 27) on the announcement.
* New ticker + thematic rebrand often sparks short-term retail/speculative buying, especially with a thin float.
* Follow-up news: Acceptance into the **AMD AI Developer Program** to advance simulation of their nanomagnetic AI accelerator architecture.
* Broader tailwinds: Growing interest in space tech, orbital computing, radiation-hardened hardware, and AI for defense/space.
This is a **high-risk, speculative micro-cap** with no current revenue from the new direction. Legacy biotech assets continue under a subsidiary.
# Management
* **CEO (and key figure)**: **Robb Knie** — long-time CEO (since 2017). He has positioned the rebrand as a signal to investors that the company is now focused on the orbital economy. He emphasizes the exclusive licenses for the nanomagnetic tech as a credible foundation.
* The company has a history of pivots (common in small biotech shells), which some view skeptically.
# Sentiment
* **Short-term**: Very bullish/hype-driven among retail and momentum traders due to the space/AI theme, ticker change, and recent volume surge. It's trading on narrative and FOMO right now.
* **Overall/Cautionary**: Mixed to skeptical among longer-term investors. Concerns include:
* No revenue, history of losses (accumulated deficit mentioned around $75M in some coverage).
* Multiple prior pivots as a biotech company.
* Execution risk on unproven space tech.
* LET ME KNOW IF YOU JHAVE ANY BETTER STOCK IN HAND